VHAM
CORT icon

Van Hulzen Asset Management’s Corcept Therapeutics CORT Stock Holding History

Van Hulzen Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,201
Closed -$459K – 364
2025
Q4 		$459K Sell
13,201
-3,389
-20% -$266K 0.03% 230
2025
Q3 		$1.38M Sell
16,590
-396
-2% -$28.7K 0.1% 133
2025
Q2 		$1.25M Buy
+16,986
New +$1.23M 0.1% 132

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Van Hulzen Asset Management's CORT Position: Q1 2026 in Review

Van Hulzen Asset Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 13,201 shares — an estimated $459K sold.

Van Hulzen Asset Management first reported a position in CORT in Q2 2025 and held it in 3 quarters. The position peaked at $1.38M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Van Hulzen Asset Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Van Hulzen Asset Management sold 13,201 Corcept Therapeutics shares in Q1 2026, an estimated $459K.
  • Van Hulzen Asset Management first reported a position in Corcept Therapeutics in Q2 2025 and held it in 3 quarters.
  • Van Hulzen Asset Management's Corcept Therapeutics position peaked at $1.38M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Van Hulzen Asset Management's 13F filing for Q1 2026, filed 14 May 2026.